×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
22048237 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
22048237 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
22351686 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
22356324 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
22389471 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
22536370 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
22608338 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
22649091 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Improved survival with MEK inhibition in BRAF-mutated melanoma.
22663011 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Improved survival with MEK inhibition in BRAF-mutated melanoma.
22663011 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
22735384 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
22743296 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
22798288 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
22805292 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
22972589 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
22972589 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
22997239 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
23020132 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
23031422 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
23031422 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
23237741 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
23248257 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
23248257 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
23273605 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
23317446 2013